292 related articles for article (PubMed ID: 31231086)
1. Predictive Factors of Antiparkinsonian Drug Reduction after Subthalamic Stimulation for Parkinson's Disease.
Samura K; Miyagi Y; Kawaguchi M; Yoshida F; Okamoto T; Kawashima M
Neurol Med Chir (Tokyo); 2019 Sep; 59(9):331-336. PubMed ID: 31231086
[TBL] [Abstract][Full Text] [Related]
2. Stimulation sites in the subthalamic nucleus and clinical improvement in Parkinson's disease: a new approach for active contact localization.
Garcia-Garcia D; Guridi J; Toledo JB; Alegre M; Obeso JA; Rodríguez-Oroz MC
J Neurosurg; 2016 Nov; 125(5):1068-1079. PubMed ID: 26848922
[TBL] [Abstract][Full Text] [Related]
3. Subthalamic Nucleus Deep Brain Stimulation Modulate Catecholamine Levels with Significant Relations to Clinical Outcome after Surgery in Patients with Parkinson's Disease.
Yamamoto T; Uchiyama T; Higuchi Y; Asahina M; Hirano S; Yamanaka Y; Kuwabara S
PLoS One; 2015; 10(9):e0138462. PubMed ID: 26394059
[TBL] [Abstract][Full Text] [Related]
4. Effect of Subthalamic Deep Brain Stimulation on Levodopa-Induced Dyskinesia in Parkinson's Disease.
Kim JH; Chang WS; Jung HH; Chang JW
Yonsei Med J; 2015 Sep; 56(5):1316-21. PubMed ID: 26256974
[TBL] [Abstract][Full Text] [Related]
5. Eight-year follow-up outcome of subthalamic deep brain stimulation for Parkinson's disease: Maintenance of therapeutic efficacy with a relatively low levodopa dosage and stimulation intensity.
Jiang L; Chen W; Guo Q; Yang C; Gu J; Xian W; Liu Y; Zheng Y; Ye J; Xu S; Hu Y; Wu L; Chen J; Qian H; Fu X; Liu J; Chen L
CNS Neurosci Ther; 2021 Nov; 27(11):1366-1373. PubMed ID: 34350691
[TBL] [Abstract][Full Text] [Related]
6. Pallidal versus subthalamic nucleus deep brain stimulation for levodopa-induced dyskinesia.
Fan SY; Wang KL; Hu W; Eisinger RS; Han A; Han CL; Wang Q; Michitomo S; Zhang JG; Wang F; Ramirez-Zamora A; Meng FG
Ann Clin Transl Neurol; 2020 Jan; 7(1):59-68. PubMed ID: 31813194
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes using ClearPoint interventional MRI for deep brain stimulation lead placement in Parkinson's disease.
Ostrem JL; Ziman N; Galifianakis NB; Starr PA; Luciano MS; Katz M; Racine CA; Martin AJ; Markun LC; Larson PS
J Neurosurg; 2016 Apr; 124(4):908-16. PubMed ID: 26495947
[TBL] [Abstract][Full Text] [Related]
8. A comparison of indirect and direct targeted STN DBS in the treatment of Parkinson's disease-surgical method and clinical outcome over 15-year timespan.
Lahtinen MJ; Haapaniemi TH; Kauppinen MT; Salokorpi N; Heikkinen ER; Katisko JP
Acta Neurochir (Wien); 2020 May; 162(5):1067-1076. PubMed ID: 32103343
[TBL] [Abstract][Full Text] [Related]
9. Relationship between electrode position of deep brain stimulation and motor symptoms of Parkinson's disease.
Zhang F; Wang F; Li W; Wang N; Han C; Fan S; Li P; Xu L; Zhang J; Meng F
BMC Neurol; 2021 Mar; 21(1):122. PubMed ID: 33731033
[TBL] [Abstract][Full Text] [Related]
10. The medical treatment of patients with Parkinson's disease receiving subthalamic neurostimulation.
Alexoudi A; Shalash A; Knudsen K; Witt K; Mehdorn M; Volkmann J; Deuschl G
Parkinsonism Relat Disord; 2015 Jun; 21(6):555-60; discussion 555. PubMed ID: 25842260
[TBL] [Abstract][Full Text] [Related]
11. Meta-analysis comparing deep brain stimulation of the globus pallidus and subthalamic nucleus to treat advanced Parkinson disease.
Liu Y; Li W; Tan C; Liu X; Wang X; Gui Y; Qin L; Deng F; Hu C; Chen L
J Neurosurg; 2014 Sep; 121(3):709-18. PubMed ID: 24905564
[TBL] [Abstract][Full Text] [Related]
12. Exhaustive, one-year follow-up of subthalamic nucleus deep brain stimulation in a large, single-center cohort of parkinsonian patients.
Tir M; Devos D; Blond S; Touzet G; Reyns N; Duhamel A; Cottencin O; Dujardin K; Cassim F; Destée A; Defebvre L; Krystkowiak P
Neurosurgery; 2007 Aug; 61(2):297-304; discussion 304-5. PubMed ID: 17762742
[TBL] [Abstract][Full Text] [Related]
13. EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson's disease.
Dafsari HS; Martinez-Martin P; Rizos A; Trost M; Dos Santos Ghilardi MG; Reddy P; Sauerbier A; Petry-Schmelzer JN; Kramberger M; Borgemeester RWK; Barbe MT; Ashkan K; Silverdale M; Evans J; Odin P; Fonoff ET; Fink GR; Henriksen T; Ebersbach G; Pirtošek Z; Visser-Vandewalle V; Antonini A; Timmermann L; Ray Chaudhuri K;
Mov Disord; 2019 Mar; 34(3):353-365. PubMed ID: 30719763
[TBL] [Abstract][Full Text] [Related]
14. Subthalamic deep brain stimulation and levodopa in Parkinson's disease: a meta-analysis of combined effects.
Vizcarra JA; Situ-Kcomt M; Artusi CA; Duker AP; Lopiano L; Okun MS; Espay AJ; Merola A
J Neurol; 2019 Feb; 266(2):289-297. PubMed ID: 29909467
[TBL] [Abstract][Full Text] [Related]
15. A prospective, controlled study of non-motor effects of subthalamic stimulation in Parkinson's disease: results at the 36-month follow-up.
Jost ST; Sauerbier A; Visser-Vandewalle V; Ashkan K; Silverdale M; Evans J; Loehrer PA; Rizos A; Petry-Schmelzer JN; Reker P; Fink GR; Franklin J; Samuel M; Schnitzler A; Barbe MT; Antonini A; Martinez-Martin P; Timmermann L; Ray-Chaudhuri K; Dafsari HS;
J Neurol Neurosurg Psychiatry; 2020 Jul; 91(7):687-694. PubMed ID: 32371534
[TBL] [Abstract][Full Text] [Related]
16. Subthalamic nucleus stimulation does not cause deterioration of preexisting hallucinations in Parkinson's disease patients.
Yoshida F; Miyagi Y; Kishimoto J; Morioka T; Murakami N; Hashiguchi K; Samura K; Sakae N; Yamasaki R; Kawaguchi M; Sasaki T
Stereotact Funct Neurosurg; 2009; 87(1):45-9. PubMed ID: 19174620
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal medication profile and cost savings in Parkinson's disease patients after bilateral subthalamic nucleus deep brain stimulation.
Ng JH; See AAQ; Xu Z; King NKK
J Neurol; 2020 Aug; 267(8):2443-2454. PubMed ID: 32367298
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors of subthalamic stimulation in Parkinson's disease: a comparative study between short- and long-term effects.
Tsai ST; Lin SH; Chou YC; Pan YH; Hung HY; Li CW; Lin SZ; Chen SY
Stereotact Funct Neurosurg; 2009; 87(4):241-8. PubMed ID: 19556833
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes following awake and asleep deep brain stimulation for Parkinson disease.
Chen T; Mirzadeh Z; Chapple KM; Lambert M; Shill HA; Moguel-Cobos G; Tröster AI; Dhall R; Ponce FA
J Neurosurg; 2018 Mar; 130(1):109-120. PubMed ID: 29547091
[TBL] [Abstract][Full Text] [Related]
20. Direct effect of subthalamic nucleus stimulation on levodopa-induced peak-dose dyskinesia in patients with Parkinson's disease.
Katayama Y; Oshima H; Kano T; Kobayashi K; Fukaya C; Yamamoto T
Stereotact Funct Neurosurg; 2006; 84(4):176-9. PubMed ID: 16905880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
